Skip to content
The Policy VaultThe Policy Vault

Thalomid (thalidomide)Medica

Histiocytic neoplasms (Langerhans cell histiocytosis or Rosai-Dorfman cutaneous disease)

Initial criteria

  • age ≥ 18 years
  • For Langerhans cell histiocytosis: single-system multifocal skin disease OR relapsed/refractory disease; OR Patient has Rosai-Dorfman cutaneous disease

Approval duration

1 year